Acta Medica Okayama 72巻 3号
2018-06 発行

R-mini CHP in ≥80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol

Miyata, Yasuhiko Department of Hematology, Nagoya Medical Center
Saito M. , Akiko Clinical Research Center, Nagoya Medical Center
Yano, Takahiro Department of Hematology, Tokyo Medical Center
Yoshida, Isao Department of Hemato-oncology, Shikoku Cancer Center
Suehiro, Youko Department of Hematology, Kyushu Cancer Center
Harada, Naoki Department of Hematology, Kyushu Medical Center
Nagai, Hirokazu Department of Hematology, Nagoya Medical Center
Publication Date
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
Document Type
Clinical Study Protocol
diffuse large B-cell lymphoma
single arm trial
Link to PubMed